Is dihexa FDA-approved, and what does the research show?

What is dihexa?

Dihexa is a synthetic peptide, a short chain of amino acids made in a laboratory ¹. Its chemists started from an analog of angiotensin IV, a six-amino-acid peptide the body makes ¹, ². They kept its first three amino acids, Nle-Tyr-Ile, and modified that fragment so the molecule would survive in blood and reach the brain ¹.

The result, named N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, was first described online in October 2012 by a group at Washington State University ¹. A 2024 paper calls it PNB-0408 ⁵. That first paper presents it as "a drug candidate," not as a medicine ¹.

Is dihexa FDA-approved?

Dihexa is not FDA-approved: Drugs@FDA lists no approved dihexa product as of November 9, 2026 ³. It is a research compound studied in rats and mice, with no human trial found ¹, ², ⁷. FDA keeps a list of bulk drug substances nominated for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act ⁴. Section 503A is the part of the law that covers pharmacy compounding.

The list, updated May 14, 2026, sorts nominated substances into three categories: under evaluation, raising significant safety concerns, and nominated without adequate support ⁴. Dihexa appears in none of the three ⁴.

So no FDA evaluation of dihexa for compounding is recorded there, and no FDA category heading describes it ⁴. FDA's January 2025 interim policy on 503A compounding sets four conditions under which FDA does not intend to act against a licensed pharmacy or physician using an unlisted bulk substance ⁹. The first is that the substance "appears in 503A Category 1" ⁹.

The policy adds that products compounded from "substances not nominated for the 503A bulks list" are "not within the scope of the policy" ⁹. Dihexa is in no category, so the first condition is not met ⁴, ⁹. There is no approved dihexa product, and no lawful route to it as a medicine appears in any source opened ³, ⁹.

See the FDA status of every peptide, updated weekly.

How does dihexa work?

The mechanism is proposed, not shown in people. The 2012 paper says dihexa binds and activates hepatocyte growth factor, or HGF, a protein that helps nerve cells grow and connect ¹. For that claim it cites the authors' own then-unpublished data ¹. Shown in cells: in rat brain neurons grown in a dish, dihexa raised the count of dendritic spines from 15 to 41 per 50 micrometers of dendrite ¹. Dendritic spines are the small knobs where one nerve cell receives signals from another.

The 2014 paper that set out the HGF mechanism in full was retracted in April 2025 ¹⁰, ⁸. The journal's notice says the retraction followed a Washington State University investigation that found figures and data "falsified and/or fabricated," and names two of the authors as solely responsible ⁸. The 2012 paper carries a 2021 notice of concern from the journal's editors about "possible image manipulation" ¹¹. The editors said then that they would await the results of a university inquiry ¹¹. A 2021 mouse study proposed a different route, the PI3K/AKT signaling pathway ².

What does the research show?

Studied in animals for memory loss. In the 2012 paper, dihexa given by mouth reversed a drug-induced learning deficit in male Sprague-Dawley rats tested in a water maze, with 8 to 10 rats per group ¹. In 24-month-old rats, three males and three females per group, daily oral dihexa shortened the time to find a hidden platform over 8 days of testing ¹. The authors note that these aged rats were not screened for memory problems first, and that the untreated group varied widely ¹. The paper does not report toxicity or adverse effects ¹.

Studied in mice for Alzheimer's disease: a 2021 study used APP/PS1 mice, a strain bred to develop Alzheimer-like changes ². Dihexa restored their spatial learning in the water maze and lowered markers of brain inflammation ². Studied in rats for Huntington's disease: a 2024 study randomized 40 male Wistar rats to three groups ⁵. One group got vehicle, one a toxin that mimics the disease, and one the toxin plus dihexa ⁵. Over five weeks, dihexa "did not protect rats from the deficits" ⁵.

Studied in rats for nerve repair: a 2021 study of sciatic nerve repair used 6 to 8 rats per group ⁶. Dihexa with stem cells, injected into the calf muscle, improved walking scores 8 to 16 weeks after the repair ⁶. A 2018 systematic review of angiotensin IV, angiotensin-(1-7), their analogs and their receptors found 32 studies that met its criteria, all of them in animals ¹².

No published human trial of dihexa was found among the sources opened on November 9, 2026, and ClinicalTrials.gov listed no registered study of it on that date ⁷. What dihexa does in people, at any dose and for any length of time, has not been studied in any source opened.

What are the side effects?

No source opened reports side effects of dihexa in people, because no human study of it was found ⁷. The 2012 rat study does not report toxicity or adverse effects ¹. The 2024 rat study tracked body weight, movement and learning for five weeks; its abstract does not mention adverse effects of dihexa, and reports no benefit ⁵. FDA has published no safety words about dihexa in the sources opened: its 503A list does not name it, so no FDA category heading applies ⁴.

What is missing is the point. Dihexa is proposed to act, in animals, on a growth factor that drives nerve cells to grow and connect ¹. That proposal rests on data the authors had not published and on a paper since retracted ¹, ⁸. No study opened reports what that does in a person over weeks or years, what dose is safe, or how it interacts with other medicines.

In sport

Dihexa is not named on WADA's 2026 Prohibited List ¹³. WADA, the World Anti-Doping Agency, also has a class S0, "Non-approved substances," prohibited at all times ¹³. Its clause reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times" ¹³. Section S2.3, "Growth factors and growth factor modulators," names "Hepatocyte growth factor (HGF)," the growth factor dihexa is proposed to act on ¹³, ¹.

FDA's records were read for the status above; no other country's regulator was checked ³. Whether S0 or S2.3 covers dihexa is a question for an athlete's anti-doping organization.

What JumpstartMD offers

JumpstartMD does not prescribe dihexa. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.